Dr. Vincent Giampapa’s Global Foundation for Human Aging Research Donates $50,000 to The Sinclair Lab at Harvard Medical School
MONTCLAIR, N.J., June 15, 2017 — “The mission of the Sinclair Lab is exactly in line with the mission of our foundation,” says Dr. Vincent Giampapa, founder of the Global Foundation for Human Aging Research, “and that’s why we’ve donated $50,000 to its ongoing efforts.” The Sinclair Lab website states it studies the processes that drive aging and age-related diseases, and works toward discovering methods for slowing down or reversing these processes. Work ranges from dissecting novel pathways and identifying target genes, to assessing small molecules that may slow the pace of aging and increase healthspan.
Dr. Giampapa met Harvard Medical School Department of Genetics faculty member and Sinclair Lab founder Dr. David Sinclair earlier this year and was impressed with his work on NMN — a molecule that appears to protect against DNA degradation and positively impact aging in mice. According to the Harvard Gazette, human trials of NMN could begin this year.
“I believe the faculty at the Sinclair Lab is doing first rate work that will have major global impact, and that’s why the foundation is supporting their mission,” says Dr. Giampapa. “Shifting our health care system into a ‘prevention and wellness’ mode will require new technologies and treatments, and those treatments must go beyond symptom suppression. Dr. Sinclair’s work with NMN is an example of this forward-thinking approach.”
The major challenges facing health care systems in the future will be demographic in nature, which underscores the need for a paradigm shift on how medical professionals think about aging. According to the Pew Research Center, global population growth will slow significantly between now and 2050. Consequently, the share of people over age 65 will increase. Some regions will feel this more than others; East Asia, for instance, is already facing stiff challenges in how to care for its aging populations. For his part, Dr. Giampapa sees the Sinclair Lab’s work as part of the solution to this slow-motion crisis.
Using Dr. Sinclair’s “ICE Mice Model,” which measures a compound’s anti-aging effects even at the genetic level, Dr. Giampapa believes companies have a promising, accelerated way of testing natural compounds’ potency and efficacy without having to wait a lifetime for human tests. Many natural compounds may have significant effects on slowing human aging, which makes this accelerated testing methodology critical.
“I look forward to witnessing new technologies help the world’s aging population experience a better quality of life, lower health care costs, and reduced dependence on prescription drugs,” concludes Dr. Giampapa.